<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02413567</url>
  </required_header>
  <id_info>
    <org_study_id>C-20000A</org_study_id>
    <nct_id>NCT02413567</nct_id>
  </id_info>
  <brief_title>Evaluation of Duodenal Mucosal Resurfacing in Subjects With Type 2 Diabetes</brief_title>
  <official_title>Evaluation of Duodenal Mucosal Resurfacing for the Treatment of Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fractyl Laboratories, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fractyl Laboratories, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the Fractyl Duodenal Mucosal Resurfacing (DMR)
      Procedure for the treatment of Type 2 Diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glycated Hemoglobin</measure>
    <time_frame>24 weeks post-procedure</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Device or procedure related Serious Adverse Events (SAEs) and Unanticipated Adverse Device Effects (UADEs)</measure>
    <time_frame>24 weeks post-procedure</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of hypo-glycemic events (blood glucose level of &lt; 56 mg/dL (3.1 mmol/L) or requiring 3rd party assistance)</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>DMR Procedure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receive the endoscopic DMR procedure in this arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DMR Procedure (Fractyl)</intervention_name>
    <description>Endoscopic procedure</description>
    <arm_group_label>DMR Procedure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  28 -75 years of age

          -  Diagnosed with Type 2 Diabetes for less than 10 years

          -  HbA1c of 7.5 - 10.0% (59-86 mmol/mol)

          -  BMI ≥ 24 and ≤ 40 kg/m2

        Exclusion Criteria:

          -  Diagnosed with Type 1 Diabetes or with a history of ketoacidosis

          -  Probable insulin production failure, defined as fasting C Peptide serum &lt;1 ng/mL
             (333pmol/l)

          -  Current use of Insulin

          -  Use of GLP-1 analogues

          -  Active and uncontrolled GERD defined as grade III esophagitis or greater

          -  Upper gastro-intestinal conditions such as ulcers, gastric varices, strictures,
             congenital or acquired intestinal telangiectasia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>28 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hopital Erasme</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Clinico de Obesidad</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università Cattolica del Sacro Cuore, Policlinico A. Gemelli</name>
      <address>
        <city>Rome</city>
        <state>Lazio</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College London Hospitals</name>
      <address>
        <city>London</city>
        <zip>NW1 2BU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's College Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Chile</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>The diabetes pandemic. Lancet. 2011 Jul 9;378(9786):99. doi: 10.1016/S0140-6736(11)61068-4.</citation>
    <PMID>21742159</PMID>
  </reference>
  <reference>
    <citation>Ismail-Beigi F. Clinical practice. Glycemic management of type 2 diabetes mellitus. N Engl J Med. 2012 Apr 5;366(14):1319-27. doi: 10.1056/NEJMcp1013127. Review.</citation>
    <PMID>22475595</PMID>
  </reference>
  <reference>
    <citation>Cummings DE. Metabolic surgery for type 2 diabetes. Nat Med. 2012 May 4;18(5):656-8. doi: 10.1038/nm.2773.</citation>
    <PMID>22561818</PMID>
  </reference>
  <reference>
    <citation>Cummings DE, Bloom SR, Rubino F. At the heart of the benefits of bariatric surgery. Nat Med. 2012 Mar 6;18(3):358-9. doi: 10.1038/nm0312-358.</citation>
    <PMID>22395701</PMID>
  </reference>
  <reference>
    <citation>Rubino F, Forgione A, Cummings DE, Vix M, Gnuli D, Mingrone G, Castagneto M, Marescaux J. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg. 2006 Nov;244(5):741-9.</citation>
    <PMID>17060767</PMID>
  </reference>
  <reference>
    <citation>Jacobsen SH, Olesen SC, Dirksen C, Jørgensen NB, Bojsen-Møller KN, Kielgast U, Worm D, Almdal T, Naver LS, Hvolris LE, Rehfeld JF, Wulff BS, Clausen TR, Hansen DL, Holst JJ, Madsbad S. Changes in gastrointestinal hormone responses, insulin sensitivity, and beta-cell function within 2 weeks after gastric bypass in non-diabetic subjects. Obes Surg. 2012 Jul;22(7):1084-96. doi: 10.1007/s11695-012-0621-4.</citation>
    <PMID>22359255</PMID>
  </reference>
  <reference>
    <citation>Umeda LM, Silva EA, Carneiro G, Arasaki CH, Geloneze B, Zanella MT. Early improvement in glycemic control after bariatric surgery and its relationships with insulin, GLP-1, and glucagon secretion in type 2 diabetic patients. Obes Surg. 2011 Jul;21(7):896-901. doi: 10.1007/s11695-011-0412-3.</citation>
    <PMID>21559794</PMID>
  </reference>
  <reference>
    <citation>Cummings DE, Overduin J, Shannon MH, Foster-Schubert KE; 2004 ABS Consensus Conference. Hormonal mechanisms of weight loss and diabetes resolution after bariatric surgery. Surg Obes Relat Dis. 2005 May-Jun;1(3):358-68. Review.</citation>
    <PMID>16925248</PMID>
  </reference>
  <reference>
    <citation>Gniuli D, Calcagno A, Dalla Libera L, Calvani R, Leccesi L, Caristo ME, Vettor R, Castagneto M, Ghirlanda G, Mingrone G. High-fat feeding stimulates endocrine, glucose-dependent insulinotropic polypeptide (GIP)-expressing cell hyperplasia in the duodenum of Wistar rats. Diabetologia. 2010 Oct;53(10):2233-40. doi: 10.1007/s00125-010-1830-9. Epub 2010 Jun 30.</citation>
    <PMID>20585935</PMID>
  </reference>
  <reference>
    <citation>Verdam FJ, Greve JW, Roosta S, van Eijk H, Bouvy N, Buurman WA, Rensen SS. Small intestinal alterations in severely obese hyperglycemic subjects. J Clin Endocrinol Metab. 2011 Feb;96(2):E379-83. doi: 10.1210/jc.2010-1333. Epub 2010 Nov 17.</citation>
    <PMID>21084402</PMID>
  </reference>
  <reference>
    <citation>Verdam FJ, Schouten R, Greve JW, Koek GH, Bouvy ND. An update on less invasive and endoscopic techniques mimicking the effect of bariatric surgery. J Obes. 2012;2012:597871. doi: 10.1155/2012/597871. Epub 2012 Aug 21.</citation>
    <PMID>22957215</PMID>
  </reference>
  <reference>
    <citation>Escalona A, Pimentel F, Sharp A, Becerra P, Slako M, Turiel D, Muñoz R, Bambs C, Guzmán S, Ibáñez L, Gersin K. Weight loss and metabolic improvement in morbidly obese subjects implanted for 1 year with an endoscopic duodenal-jejunal bypass liner. Ann Surg. 2012 Jun;255(6):1080-5. doi: 10.1097/SLA.0b013e31825498c4.</citation>
    <PMID>22534421</PMID>
  </reference>
  <reference>
    <citation>Rodriguez L, Reyes E, Fagalde P, Oltra MS, Saba J, Aylwin CG, Prieto C, Ramos A, Galvao M, Gersin KS, Sorli C. Pilot clinical study of an endoscopic, removable duodenal-jejunal bypass liner for the treatment of type 2 diabetes. Diabetes Technol Ther. 2009 Nov;11(11):725-32. doi: 10.1089/dia.2009.0063.</citation>
    <PMID>19905889</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 7, 2015</study_first_submitted>
  <study_first_submitted_qc>April 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2015</study_first_posted>
  <last_update_submitted>July 12, 2017</last_update_submitted>
  <last_update_submitted_qc>July 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

